Micell Technologies enrolls first patient in DESSOLVE II Study
The MiStent DES employs Micell’s proprietary supercritical fluid technology which applies a precisely controlled absorbable polymer – active drug (sirolimus) matrix onto a cobalt-chromium stent. DESSOLVE II is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.